Prokudina E S, Senokosova E A, Antonova L V, Krivkina E O, Velikanova E A, Akentieva T N, Glushkova T V, Matveeva V G, Kochergin N A
Researcher, Laboratory of Tissue Engineering and Intravascular Visualization; Research Institute for Complex Issues in Cardiovascular Diseases, 6 Sosnovy Blvd., Kemerovo, 650002, Russia.
Leading Researcher, Laboratory of Tissue Engineering and Intravascular Visualization; Research Institute for Complex Issues in Cardiovascular Diseases, 6 Sosnovy Blvd., Kemerovo, 650002, Russia.
Sovrem Tekhnologii Med. 2023;15(4):41-48. doi: 10.17691/stm2023.15.4.04. Epub 2023 Jul 28.
was to make a vascular patch based on regenerated silk fibroin (SF) and study its physical and mechanical characteristics, biocompatibility and matrix properties in comparison with polyhydroxybutyrate/valerate/polycaprolactone with incorporated vascular endothelial growth factor (PHBV/PCL/VEGF) and commercial bovine xenopericardium (XP) flap in experiments .
Tissue-engineered matrices were produced by electrospinning. The surface structure, physical and mechanical characteristics, hemocompatibility (erythrocyte hemolysis, aggregation, adhesion and activation of platelets after contact with the material) and matrix properties of vascular patches (adhesion, viability, metabolic activity of EA.hy926 cells on the material) were studied.
The surface of SF-based matrices and PHBV/PCL/VEGF-based tissue engineered patches had a porous and fibrous structure compared to a denser and more uniform XP flap. The physical and mechanical characteristics of SF matrices were close to those of native vessels. Along with this, tissue-engineered patches demonstrated high hemocompatible properties, which do not differ from those for commercial XP flap. Adhesion, viability, and metabolic activity of EA.hy926 endothelial cells also corresponded to the previously developed PHBV/PCL/VEGF matrix and XP flap, which indicates the nontoxicity and biocompatibility of SF matrices.
Matrices produced from regenerated SF demonstrated satisfactory results, comparable to those for PHBV/PCL/VEGF and commercial XP flap, and in the case of platelet adhesion and activation, they outperformed these patches. In total, SF can be defined as material having sufficient biological compatibility, which makes it possible to consider a tissue-engineered matrix made from it as promising for implantation into the vascular wall.
旨在制备基于再生丝素蛋白（SF）的血管补片，并与掺入血管内皮生长因子的聚羟基丁酸酯/戊酸酯/聚己内酯（PHBV/PCL/VEGF）以及商用牛异种心包（XP）瓣片进行比较，研究其物理和机械特性、生物相容性及基质特性。
通过静电纺丝制备组织工程基质。研究了血管补片的表面结构、物理和机械特性、血液相容性（红细胞溶血、聚集、血小板与材料接触后的黏附及活化）以及基质特性（EA.hy926细胞在材料上的黏附、活力、代谢活性）。
与更致密且更均匀的XP瓣片相比，基于SF的基质和基于PHBV/PCL/VEGF的组织工程补片表面具有多孔纤维结构。SF基质的物理和机械特性与天然血管相近。与此同时，组织工程补片表现出高血液相容性，与商用XP瓣片无异。EA.hy926内皮细胞的黏附、活力和代谢活性也与先前开发的PHBV/PCL/VEGF基质及XP瓣片相当，这表明SF基质无毒且具有生物相容性。
由再生SF制备的基质显示出令人满意的结果，与PHBV/PCL/VEGF及商用XP瓣片相当，在血小板黏附及活化方面，其表现优于这些瓣片。总体而言，SF可被定义为具有足够生物相容性的材料，这使得由其制成的组织工程基质有望植入血管壁。
